Service invoicing

The fundamental philosophy of the Network Genomic Medicine (NGM) is to conduct comprehensive diagnostics in any patient with a non-resectable lung tumor that clarifies all aspects of possible treatment decisions promptly and irrespective of the question of reimbursement. The participation of the attending physician and the patient in the integrated care is a prerequisite for this.

Netzwerk Genomische Medizin (NGM) Lungenkrebs

The costs for the molecular pathological diagnosis and a second opinion are covered by the health insurer for patients of the AOK Rheinland / Hamburg as part of an integrated care contract (IV) since 01.04.2014.

In 2016 more health insurance companies cover the full cost of molecular diagnostics and second opinion within the framework of the integrated care. In patients with other health insurers, the network center requests reimbursement for the individual case, so that all costs will be covered in accordance with the IV contract / standard fee.

Last update: 16. March 2016 , 15:30

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.
Share This